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ABSTRACT
Introduction:
Wilson’s disease is an autosomal recessive inherited disorder of copper
metabolism characterized by excessive deposition of copper in the liver, brain
and other tissues. There is no proper data on the cutaneous manifestations of the
disease in children that is published so far in India.
Aims & Objectives:
The aim of this study is to study the various dermatological manifestations of
Wilson’s disease in the pediatric population and to correlate it with the systemic
features and the treatment.
Methodology:
The study was conducted at the department of Dermatology, Madras Medical
College, Chennai. Thirty patients with established Wilson’s disease were taken
for the study. Detailed case history of with reference to the duration of the
disease and treatment taken were recorded. Detailed and careful examination of
skin, mucosa, hair and nail were done. Skin biopsy with special staining for
copper was done.
Results:
As with Sehgal et al, xerosis was the most common manifestation in our study.
Trichomegaly was one common association we found in the study. The skin
biopsy from the patients did not show any deposits of copper as seen by copper
staining. Blue lunula of nails and cutaneous effects of D-Penicillamine were not
found in our study.
Conclusion:
Dermatologists should be aware of the various dermatological manifestations of
Wilson’s disease and cutaneous side effects of D-Penicillamine. Although
cutaneous manifestations are non- specific in Wilson’s disese, it is mandatory to
have an astute dermatological examination of all patients with the disease.
Keywords: Wilson’s disease, Kayser-Fleischer ring, D-penicillamine
1INTRODUCTION
Wilson's disease (WD) is an inborn error of the copper
metabolism caused by mutations in the copper transporting gene,
ATP7B1. It is an autosomal recessive disease characterised by a defect
in copper transport by the hepatic lysosomes. This leads to the excessive
deposition of copper in the liver, brain and other tissues resulting in
various clinical manifestations. The treatment for the disease is based on
copper chelation with drugs such as D-penicillamine and zinc.
 Kayser-Fleischer ring2 and blue lunula of the nails are specific
dermatological findings associated with this disease. Though the disease
presents with varied cutaneous presentation, there are no proper data on
the various cutaneous lesions in children or adults that has been
published so far in India, hence the study was undertaken.
REVIEW OF
LITERATURE
2REVIEW OF LITERATURE
Wilson’s disease is a disorder of copper metabolism, autosomal
recessive in inheritance and characterised by the excessive deposition of
copper in the brain, liver and many other tissues.
HISTORY
The disease is named after Samuel Alexander Kinnier Wilson3
(1878–1937), a British physician and neurologist who described both
the disease and the pathological changes found in the brain and liver, in
1912. Dr. Wilson described the hepato lenticular degeneration in his
dissertation (1912) titled "Progressive lenticular degeneration". He was
honoured for his research, and later the disorder came to be known as
"Wilson's disease"3.
Dr.  Wilson's  work was drawn on reports  from Carl  Westphal  (in
1883), a German neurologist who termed it "pseudosclerosis"; from
William Gowers (in 1888), a British neurologist; and from Adolph
Strümpell (1898), who described the hepatic cirrhosis. John N Cumings,
a neuro pathologist found the association of copper accumulation in the
liver and brain with the disease in 19484.
3The deficiency of Ceruloplasmin in the disease was noted by
Gitlin and Scheinberg in 1952. The impaired copper excretion by the
liver in Wilson’s disease was studied by Frommer in 19745.
Cumings and Derek Denny Brown, neurologists were the first to
report treatment of the disease with the British anti-Lewisite (BAL), a
metal chelator in 1951. The first oral chelation agent that was effective
was D-penicillamine. It was discovered by John Walshe6, a British
neurologist in 1956. Walshe first introduced trientine in 1956 and also
developed tetrathiomolybdate for the use in Wilson’s disease. Zinc
acetate was initially used by Hoogenraad and Schouwink, Netherlands
physicians in the year 1961. It was further developed by Brewer7.
The genetic basis of the disease with its link to the ATP7B
mutations was first illustrated in the 1980s to 1990s by many research
groups8.
4Wilson's disease - Milestones
1912 Wilson's disease identified as an inherited disorder.
Demonstration of the Kayser-Fleischer rings2
1948-1951 Identified increased urinary copper excretion
Copper deposition in brain and liver associated with
Ceruloplasmin deficiency
1951-1952  BAL and Penicillamine therapy as treatment6
 for the disease
1961 Zinc therapy in Wilson's disease
1973-1986 Trientene and tetratiomolybdate for the treatment
1988-1991 Identification of WD gene on the long arm of
chromosome 13
(13q14.3 region)9
1990- present Continued studies on polymorphisms of ATP7B
 and disease specific mutations.
5EPIDEMIOLOGY
The incidence of Wilson’s disease is worldwide with a prevalence
ranging from 1 in 30,000 to 1 in 100,00010. One half of the patients have
CNS involvement. There are no current registries in India to determine
the incidence, but Taly et al3 in his study has found that the incidence is
more common in India than previously thought. The incidence of
Wilson disease is  found to be 10 to 30 million cases in the world.  The
heterozygote carrier rate is 1 case per 100 persons, with the genetic
mutation frequency varying from 0.3-0.7%.
 In Japan, the incidence is 1 in 30,000 population, whereas it is 1
in 100,000 population in Australia. The increased frequency of the
disease seen in asian countries is found to be due to the high rates of
consanguinity. There are certain features of Wilson's disease that are
found to be different in Asians from those in other continents11. In China
there is a tight linkage between Wilson’s disease and the two gene loci
of esterase D and Retinoblastoma gene in the chromosome 13. Skeletal
involvement, epileptic seizures, amenorrhea, leg hyperpigmentation and
cerebral white matter degeneration are commonly found in Asian
patients12.
6There are a number of case reports and data from the Western part
of the world. However limited data are available regarding the
incidence, prevalence from the Indian literature. Wadia13 and Dastur14
(in 1963 and 1968) were the first to describe Wilson’s disease from
India. Various publications of Wilson’s disease were published
subsequently.
Age at presentation:
Thomas and his colleagues analysed the mutations that are found
in the ATP7B gene15. They concluded that there is a wide age difference
in the onset of the disease. Mutations that cause complete disruption of
the ATP 7B genes16 can result in early childhood liver disease. Due to
wide age difference, the upper age limit for Wilson’s disease is
considered is 40 years and the lower age is 5 years. But the disorder has
been detected in children younger than 3 years of age and in adults older
than 70 years17.
Sex distribution:
The female patients have a fulminant presentation of Wilson
disease than the males.
7GENETICS
The  Wilson's  disease  gene  (ATP7B)  is  located  on  the
chromosome 13 (13q14.3). This gene is expressed mainly in the liver
and also in the kidney and placenta. This ATP7B gene encodes for a P-
type specific ATPase enzyme which is a cation transport enzyme18. This
enzyme helps in the transport of copper into the bile thus facilitating its
incorporation into the ceruloplasmin.
 Mutations can be detected in 90% of the patients, of which 60%
are homozygous for ATP7B mutations i.e. have two abnormal copies.
30% are heterozygotes, found to have only one abnormal copy. 10% of
patients have no detectable mutation. There are around 300 mutations in
the gene ATP7B that have been described and they are specific to each
genetic population. For example, in Caucasians, there is H1069Q
mutation, which results in the replacement of histidine by glutamine at
the position 1069 that is seen in 37–63% of cases. In China, this
mutation is very uncommon. R778L mutation which causes the
replacement of arginine to leucine at the 778 position is found to be
more common in Chinese population. Little is known about the impact
of various mutations, According to studies, the H1069Q mutation seems
8to predict about the late onset of the disease with predominantly
neurological onset16.
PRNP gene19 produces a prion protein, is found to be involved in
transporting copper in the brain. Natural mutations occurring in this
gene has been associated with the late onset of disease and neurological
involvement. Stuehler et al reported that changes in the MURR1 gene20
were associated with an earlier onset of Wilson’s disease.
Wilson’s disease is inherited autosomal recessively and hence
patients may not have family history of the condition as they may be
carriers with only one of the abnormal gene (heterozygotes). Carriers do
not manifest any symptoms and may also have insignificant
abnormalities of copper metabolism.
PATHOGENESIS
The total body copper content is normally 50-100 mg. The daily
intake of copper on an average is 2-5 mg, depending on an individual’s
intake of food enriched in copper like legumes, shellfish. Copper is a
micronutrient which is a part of various enzymes of cellular metabolism
like cytochrome C oxidase, dopamine beta-hydroxylase and superoxide
dismutase21.
9FIGURE 1: Copper metabolism in hepatocyte
Of the oral copper ingested, 50-75% of the copper that reaches the
intestine is absorbed. The absorbed copper is transported into the blood
by a transporter protein called Copper transporting ATPase 1 (ATP7A),
which is situated on the intestinal cell membrane. This pathway is not
affected in the disease. From the blood copper is taken to the liver
bound with albumin. The copper uptake occurs in the hepatocytes, the
ATOX1 chaperone protein inside the hepatocyte directs the copper to be
incorporated into the copper-containing enzymes and copper-binding
proteins (CBPs) like ceruloplasmin. The copper bound to the
metallothionein protein is taken up for storage. The rest is excreted into
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the ATP7B-regulated biliary canaliculi. ATP7B helps in the transfer of
copper to the apoceruloplasmin protein to form the copper binding ?2-
globulin protein called as ceruloplasmin.
In the majority of infants less than 6 months age copper-binding
proteins (CBP) staining may be positive. After 6 months of age, the
positive staining of CBPs for copper is found in association with liver
diseases like Wilson disease and chronic biliary disorders22 mainly.
Ceruloplasmin is the serum glycoprotein that is synthesized
mainly in the liver. It carries around 90% of the copper that is present in
the plasma. It acts as a source of copper for peripheral organs. Patients
with Wilson's disease have low ceruloplasmin levels, which is due to
decreased rate of production of ceruloplasmin in the liver. Though low
ceruloplasmin levels are seen in most patients, hypoceruloplasminemia
has no role in the course of Wilson's disease. Copper is incorporated into
the glycoprotein, ceruloplasmin in the Golgi apparatus. The copper that
is transported must cross the Golgi apparatus membrane which is
ATP7B dependant. This is diminished or absent in Wilson's disease
patients. A decrease in the incorporation of copper into ceruloplasmin
leads to a reduced circulating level of this protein. Various Other
conditions which are associated with the deficiency of ceruloplasmin
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includes the Menkes'disease, hereditary ceruloplasmin deficiency,
protein losing enteropathy, hepatic failure, nephritic syndrome, sprue
which are associated with transient ceruloplasmin deficiency23.
ATP7B and ATP7A are homologous copper-transporting
proteins. Mutations of the ATP7A gene causes the storage of copper
within the enterocytes, preventing entry of copper into the blood causing
a complete copper deficiency resulting in the condition known as
Menkes disease9. It is an X-linked recessive disorder characterized by
severe neurological impairment and connective tissue dysfunctions.
The transport of copper by the copper-transporting P-type ATPase
is defective in Wilson disease. Mutations in ATP7B can lead to a
reduction in the conversion of apoceruloplasmin protein into
ceruloplasmin. Failure to excrete the copper into the biliary canaliculi
leads to its build-up within the hepatocytes. Excess copper damages the
mitochondria24. The excess copper gets into the blood and damages the
brain, kidney and red blood cells by overloading them. Apoptotic cell
death is also accelerated by the inhibition of IAPs (inhibitor of apoptosis
proteins) caused by the excess deposits of intracellular copper.
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Excess copper can be rendered nontoxic either by complexes
formation with apo-metallothionein to produce copper-metallothionein,
or by its excretion into bile. Copper balance is maintained by the
regulation of excretion. The major route of copper excretion is
hepatobiliary.
CLINICAL FEATURES
• Asymptomatic form
It is characterized by positive laboratory findings of Wilson’s
disease with the absence of signs and symptoms suggestive of liver
disease and with no ocular or neurological manifestations25.
• Acute, chronic and fulminant hepatic forms
a) Acute hepatitis is indistinguishable of acute hepatitis of viral
origin with features of  jaundice, hepatomegaly and raised
aminotransferase enzymes.
b) Chronic hepatitis which presents with signs of portal
hypertension, hepatomegaly, splenomegaly, elevated liver
enzyme, with or without jaundice.
c) Fulminant hepatic failure which presents with clinical
manifestations of acute hepatitis and encephalopathy up to 8
13
weeks after the appearance of the clinical manifestations of liver
disease26.
• Neurological form27
This  presents  either  as  psychiatric  symptoms  such  as  altered
behaviour, speech disorders, psychoses or as neurological symptoms
such as tremors, cerebellar signs, dystonia and rigidity28.
 Clinical Features of Wilson's disease
Asymptomatic Family history of Wilson’s disease/ found by screening
family members of Wilson’s disease
Neurological Dysarthria
(45-50%) Tremors (postural, resting or kinetic)
Dystonia and Rigidity
Seizures
Cerebellar dysfunction (ataxia, intentional
Tremors, scanning speech)
Dysphonia
Hepatic Asymptomatic
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(>than 50%) Chronic hepatitis
Acute hepatitis
Cirrhosis
Fulminant hepatic failure
Psychiatric Personality changes, Depression
(20%) Psychosis
Neurosis
Others Hematuria
Renal disease- aminoaciduria, renal stones
Skeletal disease- arthritis, premature osteoporosis,
Osteomalacia
Myocardial disease: cardiomyopathy and arrhythmias
Gynaecomastia, recurrent hypokalemic muscle
weakness
glucose intolerance
The cutaneous features are present in less than 5 % of the patients and
are dealt separately.
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Hepatic dysfunction:
This is the presenting feature in 50% of the patients. The hepatic
manifestation are :
? Cirrhosis (the most common initial presentation)
? Chronic active hepatitis
? Fulminant hepatic failure
Fulminant hepatic failure as seen by the following signs:
? Ascites /distended abdomen
? Prominent abdominal veins
? Digital clubbing/astrexis
? Hematemesis
? Jaundice
? Spider nevi
? Palmar erythema
Neuropsychiatric features:
Patients who present with neuropsychiatric manifestations have
commonly cirrhosis of liver. The common neurological feature is
asymmetric tremors. This tremor is variable in character and may be
resting, kinetic or postural29.
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Early symptoms are:
? Difficulty while speaking.
? Clumsiness of the hands
? Excessive salivation
? Mask like facies
? Ataxia
? Personality changes
Late manifestations (which are rare due to early diagnosis and
treatment):
Rigidity, dystonia, spasticity, flexion contractures and seizures
Psychiatric features (10-20% of patients) include the following30:
? Emotional lability
? Impulsiveness
? Disinhibition
? Self-injurious behavior
The psychiatric abnormalities have been divided as follows:
? Behavioural, Schizophrenic, Affective and Cognitive
17
Musculoskeletal manifestations
? The arthropathy is a degenerative process similar to premature
osteoarthritis
? Symptomatic joint disease occurs after age 20 years, late in the
course of the disease.
? The arthropathy mainly involves the large joints (knees, hips) and
the spine.
? Osteochondritis dissecans, chondrocalcinosis and chondromalacia
patellae have also been noted31.
Hematologic and renal manifestations
? Hemolytic anemia is a rare manifestation.
? Coombs-negative intravascular hemolysis occurs because of the
oxidative damage to RBC by toxic levels of copper.
? Clinically, patients may show features of Fanconi syndrome,
excess renal losses of glucose, fructose, amino acids, pentose, uric
acid and defective renal acidification. The renal manifestations
are variable.
18
? Renal manifestations may be primary or secondary to the release
of copper from the liver.
? Fulminant Wilson’s disease - No clinical or lab finding has
definitive diagnostic value for fulminant Wilson disease.
? The combination of low serum alkaline phosphatase, low serum
transaminases, hemolysis, and presence of renal Fanconi
syndrome is the characteristics of fulminant Wilson’s disease.
Early recognition is critically important for good prognosis.
? Urolithiasis which is found in nearly 16% of patients which may
be due to hypercalciuria or poor acidification function.
? Nephrocalcinosis, hematuria and proteinuria can also occur.
Kayser-Fleischer rings32
? KF ring is a greenish, gold to brown coloured ring formed by the
deposition of copper in the Descemet’s membrane in the corneal
limbus.
? Copper deposits in the cornea are the cardinal sign of the disease
(reported in various series of patients with Wilson’s as being
present in 85–100% of patients with neurological/psychiatric
19
symptoms, 33–86% with hepatic disease, and 0–59% with
asymptomatic disease)
? They are due to the fine granular deposits of copper in
Descemet’s membrane at the periphery extending inward from the
Schwalbe’s line.
? Well-developed brown rings may be readily visible to the naked
eye  or  can  be  seen  with  an  ophthalmoscope  at  +40lens  or  a
gonioscope.
? It is visualised in up to 90% of individuals with symptomatic
Wilson’s disease and it is invariably present in those with
neurological manifestations.
Additional manifestations
? Eyes – Sunflower cataract
? Skeletal abnormalities include osteomalacia, osteoporosis, rickets,
fractures and polyarthritis.
? Cardiac manifestations include rhythm abnormalities and
increased autonomic tone.
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CUTANEOUS MANIFESTATIONS
? In children, 70% have at least one skin or mucosal finding including
xerosis (46%) and white bands on the nails33 (19%).
? It is classically associated with blue lunulae of the nails (10%), grey-
brown macular hyperpigmentation especially of the lower extremities
where it may have a rippled appearance and a vague greenish
discoloration of the skin of the face, neck, and genitalia.
? Hyperpigmentation which is due to increased melanin in basal cell
layer.
? Skin findings are more likely in patients with longer duration of
disease.
? Skin changes caused by long term Penicillamine treatment are as
follows34,35 :
Degenerative dermatoses -cutis laxa, anetoderma, ecchymoses
Lichenoid eruption
Mouth ulcers
Erythema multiforme
Elastosis perforans serpiginosa
Pseudoxanthoma elasticum
Pemphigus
Pemphigoid
Lymphangiectasis
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The general cutaneous characteristics include:
• Jaundice
This occurs when serum bilirubin >2.5–3.0 mg/dL. If mild, the
skin appears yellow and if severe, skin appears brown.
• Pruritus of cholestasis
Tends to be generalized and is worse in the hands and feet.
Failure to metabolize toxins and inability to filter bile salts are the
main reasons. It is centrally mediated due to increased central nervous
system opioids.
Treatments include resin cholestyramine, rifampin, naltrexone,
and in severe refractory cases consider plasmapheresis.
• Prurigo nodularis
Firm, pruritic hyperkeratotic nodules1 mm–2 cm in diameter;
usually on the extremities associated with xerosis and lichenified skin.
Histopathology shows compact hyperkeratosis with focal
parakeratosis and marked acanthosis often with pseudo epitheliomatous
hyperplasia; thickening of papillary dermal collagen often in vertical
orientation; hypertrophy and increased proliferation of dermal nerves;
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lymphocytes, histiocytes, mast cells and occasional eosinophils within
the dermis.
Treatment includes the following:
? First line: topical antipruritics (corticosteroids, pramoxine,
menthol), intralesional steroids
? Second line: ultraviolet light treatment, cryotherapy, vitamin D,
capsaicin
? Third line: naltrexone, cyclosporine, low-dose thalidomide
• Spider angiomas36 (spider nevi)
This occurs in the vascular area drained by superior vena cava in
33% of patients with cirrhosis. They will disappear with pressure and if
large  enough,  they  will  pulsate  and  they  are  often  associated  with
oesophageal varices.
It is associated with increased estrogen and estrogen/androgen
ratio or elevations in growth factors like basic fibroblast growth factor
(bFGF) and vascular endothelial growth factor.
Histology shows small dilated arterioles (0.5 cm in diameter)
from which small telengiectatic vessels radiate.
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• Bier spots
Hypopigmented, small irregular-shaped patches on the arms and
legs with surrounding blanching halo of erythema and the lesions
disappear with pressure and with limb elevation.
• Paper money skin
Needle-thin superficial capillaries seen over the upper trunk .
• Palmar erythema
They present as florid, crimson colour of palms and fingertips
(most common on the hypothenar or thenar eminences), characterised
by bilaterally symmetrical lesions.
It is also associated with increased estrogen and
estrogen/androgen ratio. It occurs due to vasodilation from increased
prostacyclins and nitric oxide that accumulation patients with liver
disease.
•Nail changes
Clubbing of nails
Leuconychia
Flat nails
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Terry’s nails - Nail finding in which the proximal two thirds of
the nail appear white, with preservation of a normal 1–3 mm band of
colour at the distal nail bed. The distal bands show telangiectasia and the
proximal area shows hyperplasia of connective tissue between nail and
bone37.
• Dupuytren’s contracture
This presents as progressive fibrosis and thickening of the tendons
in the palmar fascia that on chronic course leads to stiffness in the joints
with inability to fully extend or flex the fingers.
• Disseminated superficial porokeratosis
This presents as multiple papules and annular plaques with a
slightly elevated keratotic margin. This is likely due to decreased
humoral and cell mediated responses.
Histopathology shows presence of coronoid lamella which
consists of a parakeratotic column overlying a small area of dyskeratotic
and vacuolated cells in the epidermis. There is also a focal loss of the
granular layer. A mild lymphohistiocytic infiltrate may be seen around
capillaries in the underlying dermis.
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• Caput medusa
 This presents as dilated superficial abdominal veins due to
diversion of blood away from the portal venous system
To summarise, the cutaneous changes are as follows38:
1. Spider naevi, telengiectasia, palmer erythema and livedo
reticularis are common manifestations in children with portal
hypertension.
2. Jaundice in chronic disease.
3. Purpuric rashes due to vitamin K deficiency.
4. Diffuse hyperpigmentation of the skin due to hepato-cellular
damage.
5. Hair – sparse, thin
6. Seborrhea and acneiform eruptions on the upper part of the body
are common manifestations.
7. Decreased testicular androgens due to hepatic dysfunction leads
to fine hair in adults and gynecomastia.
8. Bier‘s spots - white areas appear on the lower extremities.
9. Nails - changes in nails with blue lunula and nail clubbing in
cirrhosis.
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STAGING39
There are 4 stages in the natural history of Wilson’s disease which
are the following:
? I  -  The  period  of  accumulation  of  copper  within  hepatic  binding
sites.
? II  -  The acute redistribution of  copper inside the liver  tissue and
release of copper ions into the circulation.
? III - The chronic accumulation of copper mainly in the brain and
extra hepatic tissues associated with progressive course and fatal
outcomes.
? IV – The restoration of copper homeostasis by using long term
chelation therapies.
COMPLICATIONS
The major complications in untreated patient are as follows40:
? Acute liver failure
? Chronic hepatic dysfunction
o Cirrhosis with portal hypertension
o Bleeding from varices
o Hepatic encephalopathy
o Hepatorenal syndrome
o Hepatocellular carcinoma
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? Most patients who present with the neuropsychiatric
manifestations have cirrhosis.
Death occurs usually by the third or fourth decades in fulminant
disease without treatment or if liver transplantation is not performed41.
DIAGNOSIS42
Wilson’s disease is diagnosed on the basis of the presence of at least 2
of the following criterias:
1. Family history of Wilson’s disease
2. KF ring
3. Low ceruloplasmin levels (<18mg/dL)
4. 24-hour urine copper >100?g/24h.
5. Free copper >25?g/dL.
6. Liver copper –gold standard
[Calculated as follows: Free copper = serum copper (in mcg/dL) – (3 x
ceruloplasmin in mg/dL)]
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INVESTIGATIONS
Biochemical Liver Tests
The levels of Serum aminotransferase are generally abnormal in
Wilson’s disease. The degree of elevation of aminotransferase activity
may be only mild. Elevated transaminases do not reflect the severity of
the liver disease.
Ceruloplasmin
? This is a132-kd protein which is synthesized mainly in the liver. It
is an acute phase reactant. It is the major carrier for copper in the
blood. It accounts for 90% of the circulating copper.
? Levels of serum ceruloplasmin can be measured enzymatically by
the copper-dependent oxidase activity or by radioimmunoassay ,
nephelometry43.
? Serum ceruloplasmin concentrations are elevated in the following
conditions:
o Acute inflammation
o Hyperestrogenemia - pregnancy, oral contraceptive pill.
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? Levels of serum ceruloplasmin are physiologically very low in
early infancy and usually peaks at higher than adult level in early
childhood (at approx 180-350 mg/L), and then settles to the adult
range44.
? Serum ceruloplasmin is typically decreased in patients with
Wilson’s disease.
o It can also be low in severe end-stage liver disease , renal or
enteric proteinuria, copper deficiency patients on parenteral
alimentation, Menkes disease, aceruloplasminemia, which
lacks the protein entirely.
o Aceruloplasminemia patients exhibit hemosiderosis but not
copper accumulation.
o Normal Serum ceruloplasmin levels are 180-350 mg/dl .In
heterozygous carriers 20% have low values. In wilson’s
disease low values are associated in 90% of patients.
Serum Copper
? The copper incorporated in ceruloplasmin in Wilson’s disease is
usually decreased in proportion to the decreased ceruloplasmin
levels in the circulation.
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? In fulminant hepatic failure due levels of serum copper may be
markedly elevated due to the sudden release of the copper from
the tissue stores.
? Normal or elevated serum copper levels with decreased
ceruloplasmin levels indicate an increase in the concentration of
free copper levels.
? Thus the serum non-ceruloplasmin bound copper or the free
copper concentration has been proposed as a diagnostic test for
Wilson’s disease. It is elevated above 25 microgram/dL in most
untreated patients. The normal value of free copper is
15microgram/dL.
? The serum free copper concentration can be elevated in the
following diseases:
o Acute liver failure
o Chronic cholestasis
o Copper intoxication due to ingestion or poisoning
? The major problem with free copper is that it is dependent on
measuring both serum copper and ceruloplasmin. Therefore it is
useful in patients for monitoring their treatment.
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Urinary Copper Excretion
The amount of copper excreted in the urine in 24- hour time may
be helpful for the diagnosis and treatment monitoring. The 24-hour
urinary excretion of copper reflects the amount of free copper in the
circulation46.
Basal measurements can provide useful diagnostic information.
There is too much variability in the copper content in spot urine
specimens for them to be utilized.
The normal 24 hr urine copper is 20-50 micrograms/24 hours. For
the diagnosis of Wilson’s disease levels should be greater than 100
mcg/24 hours.
Urinary copper excretion with D-penicillamine administration can
also be a useful diagnostic adjunctive test. This test has been
standardized in a pediatric group in which 500 mg of D-penicillamine
administered orally at the beginning and again 12 hours later during the
24-hour urine collection irrespective of body weight. Measurement of
the basal 24-hour urinary excretion of copper also forms part of the
assessment to screen the siblings of Wilson’s disease patients.
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Liver Copper Concentration
This is the gold standard test for diagnosis. Hepatic copper
content is elevated in all patients with Wilson’s disease, whether
symptomatic or not. Hepatic copper content of 20-50 ?g/g dry weight of
liver remains the best biochemical test for diagnosis47.
 Elevated hepatic copper alone is not specific for Wilson’s disease
and can occur in other liver diseases. This test is more important in
young patients in whom the hepatocellular copper is mainly cytoplasmic
and thus can be undetectable by routine histochemical methods.
Neuroimaging Studies
Magnetic resonance imaging (MRI) is a sensitive indicator for the
neurologic involvement. Basal ganglia is the most consistently involved
area, with the brain stem and thalamus also being frequently affected48.
Increased signal intensity on T2-weighted images is the characteristic
abnormality. Significant brain imaging abnormalities may be present in
some individuals even prior to the onset of symptoms.
Liver Biopsy Findings49
The histological findings in the liver include the following:
? Mild steatosis (both microvesicular and macrovesicular)
? Focal hepatocellular necrosis
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? Glycogenated nuclei in hepatocytes
? Progressive parenchymal damage and fibrosis
? Cirrhosis
? In the cases of fulminant hepatic failure, there is marked
hepatocellular degeneration and parenchymal collapse, on the
background of cirrhosis. Apoptosis of hepatocytes is also a
prominent feature
? Detection of copper in hepatocytes by routine histochemical
method is variable. In early stage, copper is found mainly in the
cytoplasm bound to metallothionein and is not detected
histochemically. Copper is found predominantly in lysosomes in
later stages.
? Copper-binding protein can be stained by a variety of staining
methods including the rhodanine or orcein stain. The more
sensitive Timms sulphur stain for copper binding protein is not
used routinely. With adequate chelation treatment, these changes
may resolve.
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? Ultrastructural analysis of liver specimens at the time when
steatosis is present reveals specific mitochondrial abnormalities
like increased intracristal space with dilatation of the tips of the
cristae, creating a cystic appearance.
? The development of histopathological features of hepatocellular
carcinoma is a rarely reported.
Figure 2: Deposition of copper in the hepatocytes
Skin biopsy
The skin biopsy of the patients can be done in early stages where
there is excessive copper deposited in the skin due to the excessive spill
over from the liver tissue. Copper is mainly deposited in skin fibroblasts
and the Wilson protein is expressed in the human skin epithelium.
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Few studies have shown that the copper in the sweat of the patients may
show an increase but other studies are conflicting. Hyperpigmentation
which is commonly observed is due to increased melanin in basal cell
layer with otherwise normal skin structure and no copper deposition50.
D-penicillamine used for treatment binds to the precursors of
intermolecular crosslinks both in collagen and elastin and thus could
lead to the alterations of these two fibrous proteins. Collagen fibrils can
be swollen and unreeved. Elastin fibers can be altered. The alterations
are mostly pronounced in the reticular dermis, were proportional to the
duration of treatment and consisted of polymorphous aggregates of
elastin connected to apparently normal elastin fibers. Lumpy-bumpy
elastic fibers are pathognomonic for penicillamine-induced elastosis.
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The "rhodanine" method for the demonstration of Copper51:
Fixation: 10% neutral buffered formalin.
Embedding: Paraffin sections cut at 6 microns
Solutions:
Rhodanine saturated solution (stock) -
p-Dimethylaminobenzylinene-rhodanine  0.2 g
Absolute ethanol 100 ml
Rhodanine solution (working) -
Rhodanine saturated solution (stock) 6 ml
Distilled water 94 ml
Diluted Mayer's hematoxylin
Mayer's hematoxylin 50 ml
Distilled water 50 ml
0.5% aqueous sodium borate (borax)
Technique51:
1. Hydrate slides with distilled water.
2. Incubate slides in rhodanine working solution at 37 degree C for
18 hours.
3. Wash slides well in several changes of distilled water.
4. Stain slides in diluted Mayer's hematoxylin for 10 minutes.
5.  Rinse slides with distilled water.
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6. Quickly rinse slides in 0.5% sodium borate.
7.  Rinse slides with distilled water.
8. Dehydrate slides through 95% alcohol to absolute ethanol, clear,
and coverslip with a synthetic mountant.
Results:
Copper - orange/red52.
Tissue elements - light blue.
Genetic Studies
Molecular genetic studies are available for clinical use, but only
pedigree analysis using haplotypes based on the pattern of di- and
trinucleotide repeats around ATP7B (Wilson’s disease gene) is
commercially available from specific clinical labs. Prenatal testing can
also be performed but has limited application clinically since diagnosis
early in life allows appropriate timing for treatment53.
Family Screening
The first-degree relatives of any patient who are newly diagnosed
must be screened for Wilson’s disease. Assessment should include brief
history, physical examination, biochemical tests of hepatic system
function and Serum ceruloplasmin.
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Kayser-Fleischer rings should be looked for by slit-lamp
examination. The basal 24-hour urinary copper excretion should be
measured. Genotype or haplotype studies based on findings in the
proband can be performed54.
DIFFERENTIAL DIAGNOSIS55
? Menke disease
? Autoimmune chronic active hepatitis
? Aceruloplasminemia
? Glycogen-storage disease
? Hepatocellular adenoma
? Cirrhosis
? ?1-antitrypsin deficiency
? Chronic anemia
? Hereditary hemochromatosis
? Multiple sclerosis
? Huntington disease
? Depression
? Neurodegenerative disease
? Nephrotic syndrome
? Acquired copper deficiency
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TREATMENT
The drugs that are available for treatment include:
? D-penicillamine
? Trientine
? Zinc
? Tetrathiomolybdate
? Dimercaprol
D-PENICILLAMINE57
Penicillamine is D-dimethyl cysteine. The D-isomer is used
clinically, although the L-isomer also forms chelation complexes.
Penicillamine is an effective chelator of copper, mercury, zinc, and lead.
It promotes the excretion of these metals in the urine.
Absorption, Distribution, and Excretion: Penicillamine is well
absorbed (40% to 70%) from the GI tract. Food, antacids, and iron
reduce its absorption. Hence it is administered one hour before meals.
Peak concentrations in blood are obtained between 1 and 3 hours after
administration. Hepatic biotransformation is responsible for most of the
degradation of penicillamine. Little amount of the drug is excreted
unchanged. Metabolites are found in both urine and faeces.
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Penicillamine is available for oral administration. The drug should
be given on an empty stomach to avoid interference by metals in food.
Penicillamine is used in the treatment of Wilson's disease, cystinuria,
and  rheumatoid  arthritis.  For  the  treatment  of  Wilson's  disease,  1  to  2
g/day usually is administered in four doses. The urinary excretion of
copper should be monitored to determine whether the dosage of
penicillamine is adequate.
Dosing in children is 20 mg/kg/day rounded off to the nearest 250
mg and given in two or three divided doses.
It interferes with the pyridoxine action and hence supplemental
pyridoxine should be given (25–50 mg/day).
The treatment adequacy can be monitored by measuring 24- hour
urinary copper excretion while on treatment. For long-term treatment,
the most important sign of efficacy is a maintained clinical and
laboratory improvement.
In patients with symptomatic liver disease improvement in
clinical signs and lab improvement of liver function occurs during the
first 6 months of treatment. Lack of compliance to treatment causes the
liver disease to progress resulting in liver failure
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In patients with neurological Wilson’s disease, improvement in
the symptoms may take up to three years. Worsening of neurologic
symptoms has been reported in patients on treatment.
Adverse effects:
The hematological system also may be affected. Patients may
have leukopenia, aplastic anemia or agranulocytosis. These may occur at
any time during therapy. They may be fatal. Careful monitoring of
patients on treatment is mandatory.
Renal toxicity induced by penicillamine is manifested as
reversible proteinuria, hematuria but it may progress to the nephrotic
syndrome with membranous glomerulopathy. Toxicity to the pulmonary
system is uncommon. Less serious side effects include nausea,
vomiting, diarrhoea, dyspepsia, anorexia, and a transient loss of taste for
sweet and salt, which is relieved by supplementation of the diet with
copper.
Contraindications to penicillamine therapy include pregnancy, a
previous history of penicillamine-induced agranulocytosis or aplastic
anemia or the presence of renal insufficiency.
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Cutaneous adverse effects58:
 With long-term use, penicillamine induces several cutaneous
lesions including urticaria, macular or papular reactions, pemphigoid
lesions, lupus erythematosus, dermatomyositis and adverse effects on
collagen. Other less serious reactions such as dryness and scaling can
also occur. Cross-reactivity with penicillin may be responsible for some
episodes of urticarial or maculopapular reactions. Generalized edema,
pruritus and fever occur in one-third of patients taking penicillamine.
The other cutaneous side effects include pruritus, erythema
multiforme, progeric changes in the skin, lichen planus, and aphthous
stomatitis.
Elastosis perforans serpiginosa:
The D-penicillamine causes a decrease in the rate of synthesis of
elastic fibers in papillary dermis .It also causes an over-proliferation of
elastic fibers in the mid-dermis resulting in a characteristic appearance
of bramble bush. The abnormal elastin formed is ultimately extruded
through the epidermis.
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Pseudoxanthoma elasticum:
Copper is responsible for elastin cross linking by acting as a co-
factor for lysyl oxidase enzyme .D-Penicillamine inhibits lysyl oxidase
resulting in interference with normal tissue maturation
ZINC
 Zinc is the therapy of choice for patients presenting with hepatic
symptoms without any neurological or psychiatric symptoms. Zinc has
proven efficacy in Wilson disease and is essentially nontoxic.
The mechanism of action of zinc is it produces a negative copper
balance by blocking intestinal absorption of copper. It induces hepatic
metallothionein synthesis which sequesters additional toxic copper. All
presymptomatic patients should be treated prophylactically, since the
disease is close to 100% penetrant.
Recommended adult dose for all the above indications is 50 mg of
elemental zinc three times daily, each dose separated from food and
beverages other than water by at least 1 hour, and separated from
trientine or penicillamine doses by at least 1 hour59.
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TRIENTINE
Trientine60 is a chelator with a polyamine-like structure
chemically distinct from D-penicillamine. For initial medical therapy of
patients with hepatic decompensation trientine is preferred. Zinc should
not be ingested simultaneously with trientine, as it will chelate zinc and
form therapeutically ineffective complexes; the two drugs should be
separated by at least 1 hour.
Recommended adult dosage for drugs is 500 mg twice daily, each
dose at least 1/2 h before or 2 h after meals. In children, the dose used is
20 mg/kg/day given in two or three divided doses.
Other treatments
For initial neurologic therapy, tetrathiomolybdate is emerging as
the drug of choice because of its rapid action, preservation of neurologic
function, and low toxicity. Penicillamine and trientine should be avoided
because they each have a high risk of worsening the neurologic
condition, zinc does not itself cause neurologic worsening. Although
hepatic transplantation may improve neurologic symptoms, it does so
only by removing copper, which can be done more safely and
inexpensively with anticopper drugs. Pregnant patients should be treated
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with zinc or trientine throughout pregnancy but without tight copper
control as copper deficiency can be teratogenic.
Diet
Copper should be restricted to less than 1.5 mg/day61.
Drinking water
Allowed copper levels are up to 1.2 parts per million (ppm), this
is higher than what is safe for the Wilson’s patient.
Liver Transplantation
Liver transplantation is indicated in acute liver failure
decompensated liver disease, resistant medical treatment. Less definite
indications for liver transplantation is for the patients with severe
neurological disease62.
FUTURE TRENDS
Patients need lifelong medication and physicians are faced with
the results of non-adherence totherapy. Gene therapy and hepatocyte
transplantation represent the future curative treatments for Wilson’s
disease.
AIMS OF THE
STUDY
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AIMS OF THE STUDY
1. To study the various dermatological manifestations of Wilson’s
disease in the pediatric population.
2. To correlate the dermatological manifestations with the systemic
features and the treatment.
3. To study the copper deposition in the skin by histopathology.
MATERIALS
AND
METHODS
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MATERIAL AND METHODS
STUDY DESIGN: Prospective observational study
STUDY PERIOD: September 2013 – August 2014
INCLUSION CRITERIA:
Patients diagnosed as a case of Wilson’s disease.
Patients less than 18 years of age.
Parents willing to participate in the study.
EXCLUSION CRITERIA:
Patients more than 18 years of age.
Parents not willing to participate in the study.
SAMPLE SIZE:
The study was conducted at the department of Dermatology,
Rajiv Gandhi Government General hospital, Chennai. Patients with
established Wilson’s disease attending the Medical Gastroenterology
department at Institute of Child Health were taken for the study. Thirty
patients were included in the study.
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METHOD OF STUDY
Patients diagnosed as Wilson’s disease, less than 18 years of age
were selected for the study. The patients were divided as either
treatment naïve patients or the patients on treatment. Informed consent
was obtained from the parents. Detailed case history and clinical
examination were recorded as per the proforma. The specific
dermatological examination with respect to skin, mucosa, hair and nail
were recorded and clinical photographs were taken with the parent’s
consent.
A complete dermatological examination was done under the
following categories:
1. General examination
2. Nutritional changes
3. Vascular changes
4. Infections
5. Pigmentary changes
6. Mucosal changes
7. Hair changes
8. Nail changes
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INVESTIGATIONS
1. Blood haemogram
2. Liver function test
3. Serum ceruplasmin levels
4. 24 hour urinary copper levels
5. Imaging studies
6. Upper gastrointestinal scopy
7. Histopathological examination of skin
- Special stain for copper
OBSERVATIONS
AND
RESULTS
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OBSERVATION AND RESULTS
AGE DISTRIBUTION
In this study, most of the patients were in the age group of 6 to 9
years, followed by the 13 to 16 years age group. The youngest patient
was 6 years of age and the oldest 16 years of age. The mean age in the
study was 10.7 ± 2.9 years, the range being 6 – 16 years.
TABLE 1: AGE DISTRIBUTION
AGE
GROUP(YEARS)
NO. OF PATIENTS PERCENTAGE
6-9 12 40 %
10-12 8 26.6%
13-16 10 33.3%
0
2
4
6
8
10
12
06 to 09 10 to 12 13 to 16
FIGURE 1: AGE DISTRIBUTION
NO. OF PATIENTS
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AGE OF ONSET:
The age of onset of the disease was varied with the mean age of
onset 8.8 years, the range being 2 – 16 years.
TABLE 2: AGE OF ONSET OF DISEASE
AGE
GROUP(YEARS)
NO. OF PATIENTS PERCENTAGE
2-4 1 3.3 %
5-9 18 60 %
10-16 11 36.7 %
0
5
10
15
20
2 TO 4 5 TO 9 10 TO 16
FIGURE 2: AGE OF ONSET OF DISEASE
NO. OF PATIENTS
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SEX DISTRIBUTION
Among the 30 patients with Wilson’s disease 20(66.67%) were
male and 10(33.33%) were females. Males outnumbered females with
the male to female ratio was found to be 2:1.
TABLE 3: SEX DISTRIBUTION
SEX NUMBER PERCENTAGE
MALE 20 66.67%
FEMALE 10 33.33%
0
10
20
30
MALES
FEMALES
TOTAL
FIGURE 3: SEX DISTRIBUTION
CASES
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DURATION
The mean duration of the disease 21.7 months .The range being 1
week to 9 years. Majority of the patients had the disease for more than 6
months with 2 children having the disease for more than 5 years.
TABLE 4: DURATION OF DISEASE
DURATION OF
DISEASE
NO. OF PATIENTS PERCENTAGE
1 WEEK–6 MONTHS 13 43.3%
6 MONTHS–1 YEAR 7 23.3%
1 YEAR – 5 YEARS 8 26.6%
5 YEARS–10 YEARS 2 6.6%
0 5 10 15
1 WEEK – 6 MONTHS
6 MONTHS – 1 YEAR
1 YEAR – 5 YEARS
5 YEARS – 10 YEARS
FIGURE 4: DURATION OF DISEASE
NO. OF PATIENTS
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FAMILY HISTORY
Of the 30 patients with Wilson’s disease, 7 patients had family
history of similar illness in the siblings with 3 patients who had death of
a sibling due to the disease.
TABLE 5: FAMILY HISTORY
FAMILY HISTORY NO. OF PATIENTS PERCENTAGE
POSITIVE 7 23.3%
NEGATIVE 23 76.7%
23.3
76.7
FIGURE 5: FAMILY HISTORY
POSITIVE
NEGATIVE
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TREATMENT
Among the 30 patients, 19 patients (63.3%) had undergone
treatment and 11 patients (36.6%) were treatment naïve.
TABLE 6: TREATMENT DETAILS
NO. OF PATIENTS PERCENTAGE
UNTREATED
PATIENTS
11 36.6%
TREATED
PATIENTS
19 63.3%
0
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20
UNTREATED PATIENTS TREATED PATIENTS
FIGURE 6: TREATMENT DETAILS
NO. OF PATIENTS
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The mean duration of the treatment taken was 32.4 months, the
range being 2 months to 9 years. Among the treated patients, 15 patients
(78.9%) were on tablet D-penicillamine and 4 patients (21%) were on
tablet Zinc.
TABLE 7: TREATMENT
TREATMENT NO. OF PATIENTS PERCENTAGE
D-PENICILLAMINE 15 78.9%
ZINC 4 21%
78.9
21
FIGURE 7: TREATMENT
D-PENICILLAMINE
ZINC
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SYSTEMIC ONSET
In our study of 30 patients, 22 patients (73.3%) had hepatic onset
of  the  disease  and  8  patients  (26.7%)  had  neurological  onset  of  the
disease.
TABLE 8: SYSTEMIC ONSET
ONSET
TREATED
PATIENTS
UNTREATED
PATIENTS
TOTAL
PATIENTS
HEPATIC 16 6 22
NEUROLOGICAL 4 4 8
TREATED PATIENTS
UNTREATED PATIENTS
TOTAL PATIENTS
0
5
10
15
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25
FIGURE 8: SYSTEMIC ONSET
TREATED PATIENTS
UNTREATED PATIENTS
TOTAL PATIENTS
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KAYSER-FLEISCHER RING
Among the 30 patients, 16(53.3%) of them presented with KF
ring; out of which 11 patients (68.7%) had hepatic onset of disease and
5 patients (31.2%) had neurological onset of disease.
TABLE 9: KF RING
HEPATIC
ONSET
NEUROLOGIC
ONSET
TOTAL
KF RING 11 5 16
0
2
4
6
8
10
12
14
16
18
KF RING
FIGURE 9: KF RING
HEPATIC ONSET
NEUROLOGIC ONSET
TOTAL
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Of the 16 patients with KF ring, 9 patients (56.2%) were on
treatment and 7 patients (43.7%) were treatment naïve.
TABLE 10: KF RING
TREATED
PATIENTS
UNTREATED
PATIENTS
TOTAL
KF RING 9 7 16
0 5 10 15 20
KF RING
FIGURE 10: KF RING
TOTAL
UNTREATED PATIENTS
TREATED PATIENTS
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MALNUTRITION
Malnutrition as measured by low weight for age percentiles was
found in 5 patients (16.7%), out of which 4 had hepatic onset and 1
neurological onset.
TABLE 11: MALNUTRITION
HEPATIC
ONSET
NEUROLOGIC
ONSET
TOTAL
MALNUTRITION 4 1 5
0 1 2 3 4 5
MALNUTRITION
FIGURE 11: MALNUTRITION
TOTAL
NEUROLOGIC ONSET
HEPATIC ONSET
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DERMATOLOGICAL MANIFESTATIONS
28 patients (93.3%) had atleast one cutaneous, mucosal, hair or
nail findings. 27 patients(96.4 %) had cutaneous findings, 11 patients
(39.2%) had mucosal findings, 14 patients(50%) had hair findings and
18 patients (64.2%) had nail findings. 4 patients had all the above
findings.
TABLE 12: DERMATOLOGICAL MANIFESTATIONS
FINDINGS NO. OF PATIENTS PERCENTAGE
CUTANEOUS 27 96.4 %
MUCOSA 11 39.2%
HAIR 14 50%
NAIL 18 64.2%
ALL 4 14.2 %
62
CUTANEOUS MANIFESTATION
Of the cutaneous manifestations, xerosis was the most common
manifestation in 70.3 % patients, followed by pigmentation in 40.7 %
and infection in 33.3 %.
0
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FIGURE 12: DERMATOLOGICAL
MANIFESTATIONS
No of Patients
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TABLE 13: CUTANEOUS MANIFESTATION
CUTANEOUS
MANIFESTATION
NO OF PATIENTS PERCENTAGE
PRURITUS 6 22.2%
ICTERUS 6 22.2%
PIGMENTATION 11 40.7%
VASCULAR 5 18.5%
XEROSIS 19 70.3%
INFECTIONS 9 33.3%
OTHERS 16 59.2 %
0 5 10 15 20
PRURITUS
ICTERUS
PIGMENTATION
VASCULAR
XEROSIS
INFECTIONS
OTHERS
FIGURE 13: CUTANEOUS MANIFESTATIONS
NO OF PATIENTS
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Icterus and pruritus were seen in 6 patients (22.2 %) each and
were associated with portal hypertension in 5 patients (83.3 %).
TABLE 14: ICTERUS AND PRURITUS
NO. OF
PATIENTS
WITH
PORTAL HT
PERCENTAGE
PRURITUS 6 5 22.2%
ICTERUS 6 5 22.2%
PRURITUS
ICTERUS
2
3
4
5
6
FIGURE 14: ICTERUS AND PRURITUS
WITH PORTAL HT
NO. OF PATIENTS
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PIGMENTARY CHANGES
Pigmentary changes in the form hyperpigmentation was observed
in 8 patients (29.6%) mainly involving the lower extremities, out of
which 7 patients had hepatic onset, 5 patients associated with portal
hypertension and 7 patients were treatment naïve. Pityriasis alba was
observed in 2 patients (7.4 %), both were malnourished. Acanthosis
nigricans was observed in one patient.
TABLE 15: PIGMENTARY CHANGES
PIGMENTARY CHANGES
NO. OF
PATIENTS
PERCENTAGE
HYPERPIGMENTATION 8 29.6%
PITYRIASIS ALBA 2 7.4%
ACANTHOSIS NIGRICANS 1 3.7%
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NIGRICANS
FIGURE 15: PIGMENTARY CHANGES
NO. OF PATIENTS
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TABLE 16: HYPERPIGMENTATION
SIGN
HEPATIC
ONSET
NEUROLOGIC
ONSET
PORTAL
HT
HYPERPIGMENTATION 7 1 5
VASCULAR CHANGES
The vascular changes consisted of spider nevi and purpura in 2
patients (7.4 %) each and palmar erythema in 1 patient, mainly
associated with portal hypertension.
HEPATIC ONSET
NEUROLOGIC ONSET
PORTAL HT
0
1
2
3
4
5
6
7
HYPERPIGMENTATION
FIGURE 16: HYPERPIGMENTATION
HEPATIC ONSET
NEUROLOGIC ONSET
PORTAL HT
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TABLE 17: VASCULAR CHANGES
VASCULAR
CHANGES
NO. OF PATIENTS PERCENTAGE
SPIDER NEVI 2 7.4%
PURPURA 2 7.4%
PALMAR
ERYTHEMA
1 3.7%
0
1
2
SPIDER NEVI
PURPURA
PALMAR
ERYTHEMA
FIGURE 17: VASCULAR CHANGES
NO. OF PATIENTS
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XEROSIS
Xerosis was the most common manifestation in our study in 70.3
% patients and occurred in all children with malnutrition. It was seen in
52.6 % treated patients and 47.3 % treatment naïve patients.
TABLE 18: XEROSIS
XEROSIS TOTAL PATIENTS PERCENTAGE
UNTREATED PATIENTS 9 47.3%
TREATED PATIENTS D-
PENICILAMINE
8 42.1%
TREATED PATIENTS
ZINC
2 10.5%
FIGURE 18: XEROSIS
UNTREATED PATIENTS
TREATED PATIENTS D-
PENICILAMINE
TREATED PATIENTS ZINC
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Of the 19 patients with xerosis, 15 patients with xerosis had
hepatic onset and the remaining had neurological onset.
TABLE 19: XEROSIS
XEROSIS NO. OF PATIENTS PERCENTAGE
HEPATIC 15 78.9 %
NEUROLOGICAL 4 21 %
PORTAL HT 5 26.3 %
NO. OF PATIENTS
0
5
10
15
FIGURE 19: XEROSIS
NO. OF PATIENTS
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INFECTIONS
In  this  study,  9  patients  (30  %)  had  infections.  The  common
infections encountered were pityrisis versicolor, wart, molluscum
contagiosum, impetigo in 2 patients each and scabies was seen in 1
patient.
TABLE 20: INFECTIONS
INFECTIONS
NO. OF
PATIENTS
PERCENTAGE
PITYRIASIS VERSICOLOR 2 7.4 %
WART 2 7.4 %
MOLLUSCUM CONTAGIOSUM 2 7.4 %
IMPETIGO 2 7.4 %
SCABIES 1 3.7 %
0
1
2
3
4
FIGURE 20: INFECTIONS
NO. OF PATIENTS
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OTHER CUTANEOUS FINDINGS
The other cutaneous findings that were found in the patients were
acne vulgaris seen in 3 patients, seborrheic dermatitis in 2 patients,
keratosis pilaris over the forearms in 2 patients, atrophic patches over
the legs seen in 2 patients, atopic dermatitis in 2 patients. Café au lait
macule, urticaria, gynaecothelia, striae, phrynoderma were seen in 1
patient each. Phrynoderma was associated with malnutrition and striae
was associated with portal hypertension.
TABLE 21: OTHER CUTANEOUS FINDINGS
CUTANEOUS NO. OF PATIENTS PERCENTAGE
ACNE 3 11.1 %
SEBORRHEIC DERMATITIS 2 7.4 %
KERATOSIS PILARIS 2 7.4 %
ATROPHY 2 7.4 %
CALM 1 3.7 %
ATOPIC DERMATITIS 2 7.4 %
GYNAECOTHELIA 1 3.7 %
STRIAE 1 3.7 %
URTICARIA 1 3.7 %
PHRYNODERMA 1 3.7 %
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MUCOSAL INVOLVEMENT
Mucosal involvement was seen in 11 patients (36.7%). 6 patients
had  cheilitis  out  of  which  2  children  were  malnourished.  Oral
candidiasis was seen in 4 patients and hyperpigmentation of the tongue
was seen in 1 patient.
TABLE 22: MUCOSAL INVOLVEMENT
MUCOSA NO. OF PATIENTS PERCENTAGE
CHEILITIS 6 54.5 %
CANDIDIASIS 4 36.3 %
PIGMENTATION 1 9.0 %
TOTAL 11
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CHEILITIS
CANDIDIASIS
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FIGURE 21: MUCOSAL INVOLVEMENT
NO. OF PATIENTS
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Among the patients with mucosal involvement; 10 patients had
hepatic onset and 1 patient had neurological onset, 6 patients were on
treatment and 5 were treatment naïve.
TABLE 23: MUCOSAL INVOLVEMENT
MUCOSAL
INVOLVEMENT
NO. OF PATIENTS PERCENTAGE
HEPATIC 10 90.9 %
NEUROLOGICAL 1 9.0 %
TREATED 6 54.5 %
UNTREATED 5 45.4 %
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FIGURE 22: MUCOSAL INVOLVEMENT
NO. OF PATIENTS
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HAIR INVOLVEMENT
In our study, hair involvement was seen in 14 patients(46.6%).
Trichomegaly was the most common manifestation seen in 9 patients
(64.3%) followed by sparse hair in 5 patients.
TABLE 24: HAIR INVOLVEMENT
HAIR
INVOLVEMENT
NO. OF PATIENTS PERCENTAGE
SPARSE HAIR 5 35.7 %
TRICHOMEGALY 9 64.3 %
TOTAL 14
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FIGURE 23: HAIR INVOLVEMENT
NO. OF PATIENTS
75
TRICHOMEGALY
Trichomegaly was one of the common hair manifestation found in
our study. Out of the 9 patients with trichomegaly; 6 patients were boys
and 3 patients were girls; 4 patients had hepatic onset and 5 patients had
neurological  onset  of  the  disease;  7  patients  were  on  treatment  and  2
patients were treatment naïve. 8 of the patients had associated KF ring
and any one cutaneous finding.
TABLE 25: TRICHOMEGALY
HEPATIC NEURO TREATED UNTREATED MALE FEMALE
4 5 2 7 3 6
0 1 2 3 4 5 6 7 8
NO OF PATIENTS
FIGURE 24: TRICHOMEGALY
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MALE
UNTREATED
TREATED
NEURO
HEPATIC
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NAIL INVOLVEMENT
According to our study, nail involvement was seen in 18 patients
(60%). The common nail finding was leuconychia seen in 9 patients
(50%), followed by clubbing seen in 5 patients with portal hypertension
,pitting in 3 patients and Beau’s lines in 2 patients. 1 patient with portal
hypertension had both clubbing and leuconychia.
TABLE 26: NAIL INVOLVEMENT
NAIL NO. OF PATIENTS PERCENTAGE
PITTING 3 16.7%
LEUCONYCHIA 9 50 %
CLUBBING 5 27.8%
BEAU’S LINES 2 11.1 %
16.7
50
27.8
11.1
FIGURE 25: NAIL CHANGES
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The nail involvement was seen in 15 patients with hepatic onset
of disease and 3 patients with neurological onset. Out of the 18 patients,
9 patients were on treatment and 9 patients were treatment naïve.
TABLE 27: NAIL INVOLVEMENT
HEPATIC NEURO TREATED UNTREATED
15 3 9 9
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FIGURE 26: NAIL INVOLVEMENT
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INVESTIGATIONS
The investigations done were routine investigations to confirm the
diagnosis including routine liver function tests, Serum ceruloplasmin
levels and 24 hr urinary copper levels. MRI of brain in cases of neuro
Wilson and USG abdomen,upper esophageal scopy in cases of hepatic
onset  disease  were  done.  The  skin  biopsy  was  done  and  stained  with
special stain of copper to see for demonstration of copper in the skin and
subcutis.
SKIN BIOPSY
A  4  mm  punch  biopsy  was  taken  from  the  normal  skin  of  10
patients and was stained with Eosin & hematoxylin and Copper
Rhodanine staining. The results showed than the skin was normal on
H&E stain and on Rhodanine staining did not show any deposits of
reddish brown copper in the dermis or periappendageal areas.
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SERUM CERULOPLASMIN
In our study, 6 patients had serum ceruloplasmin levels less than
20 mg/dl and 24 patients had levels between 20 – 50 mg/dl.
TABLE 28: SERUM CERULOPLASMIN
SERUM
CERULOPLASMIN
NO. OF
PATIENTS
PERCENTAGE
< 20 mg 6 20 %
20– 50mg 24 80 %
0 5 10 15 20 25 30
< 20 mg
20– 50mg
FIGURE 27: SERUM CERULOPLASMIN
NO. OF PATIENTS
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24 HOURS URINARY COPPER
24 hour urinary copper was found to be normal in 14 patients in
our study and 8 patients had values between 300 to 600 microgram/ 24
hours.
TABLE 29: 24 HR URINARY COPPER
24 HR URINARY
COPPER(MICROGRAM)
NO. OF
PATIENTS
PERCENTAGE
<60 14 46.7 %
60 – 100 3 10 %
100 – 300 5 16.7%
300 – 600 8 26.7 %
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100 – 300
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FIGURE 28: 24 HOUR URINARY COPPER
NO. OF PATIENTS
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MRI FINDINGS
MRI findings of increased T2 intensities in Globus pallidus was
seen in 6 patients of Wilson disease with neurological onset in our
study.
ENDOSCOPY
Upper gastrointestinal endoscopy was done for all patients with
hepatic onset of the disease.
DEATH
In our study,  there was 1 patient  who died due to hepatic failure
with severe portal hypertension.
FIGURE A: KAYSER FLEISCHER RING
FIGURE A(1): KAYSER FLEISCHER RING
FIGURE A (2): KAYSER FLEISCHER RING AND TRICHOMEGALY
FIGURE A(3): KAYSER FLEISCHER RING ON SLITLAMP
EXAMINATION
FIGURE B: ICTERUS AND ACNEIFORM ERUPTIONS
FIGURE B(1) : GYNAECOTHELIA
FIGURE B(2) : XEROSIS
FIGURE B(3): ACANTHOSIS NIGRICANS
FIGURE C : HYPERPIGMENTATION WITH ATROPHIC SCARRING
FIGURE C(1) : PHRYNODERMA
FIGURE D : MOLLUSCUM CONTAGIOSUM
FIGURE D(1) : VERRUCA VULGARIS
FIGURE E : URTICARIAL WHEALS
FIGURE F : CHEILITIS
FIGURE G : TRICHOMEGALY
FIGURE H : LEUCONYCHIA
FIGURE I : RHODANINE STAINING OF SKIN SHOWING NO
COPPER DEPOSITS
FIGURE I(1) : RHODANINE STAINING OF SKIN SHOWING NO
COPPER DEPOSITS
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DISCUSSION
Wilson’s disease is a rare autosomal recessive disorder with a
disease prevalence estimated to be 1 in 30,000 with a gene frequency of
0.56%. Very few studies have been done in the pediatric population like
the studies by Sanchez-Albisua63 et al with 26 children, M Seyhan33 et al
with 37 children and Yuce34 et al with 33 children. The largest sample is
described by Dhawan65 et  al  from King’s  College  Hospital,  in  London,
with 74 children. Our study had a study sample of 30 children diagnosed
with Wilson’s disease.
TABLE 30: STUDY SAMPLE
STUDY SAMPLE SIZE
M Seyhan et al33 37
Sanchez –Albisua et al63 26
Yuce et al34 33
Dhawan et al65 74
Present study 30
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AGE DISTRIBUTION
In our study of Wilson’s disease most of the patients were in the
age group of 6 to 9 years (40 %), followed by the 13 to 16 years (33.3%)
age group. The youngest patient was 6 years of age and the oldest 16
years of age. The mean age in the study was 10.7 ± 2.9 years which is
similar to other studies with pediatric patients and the range being 6 – 16
years.
Stephania66 et al in their study on Wilson’s disease observed that
patients were 2.8 to 15.1 years old, with a mean age of 8.8 ± 0.9 years.
Age at diagnosis in the sample described by Sanchez-Albisua63 et al was
9.8 ±3.4 years and in Yuce34 et al was 10.1 ± 2.5 years.
Panagariya A67 et al in their study found the mean age of onset of
Wilson’s disease to be 13.2 years. M Seyhan33 et al in their study
observed the mean age to be 11.5 ± 3.3 years (range, 4 – 17 years).
Thus the mean age of onset of the disease of 8.8 years ( range = 2
– 16 years) in our study correlated with the other studies mentioned with
greater proportion of patients in the 6- 9 years age group.
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SEX DISTRIBUTION
In our study of 30 patients, 20(66.7%) were male and 10(33.3%)
were females. Males outnumbered females and the male to female ratio
was found to be 2:1.
Panagariya67 A et al noted a male preponderance (67%) in their
study, which has earlier been documented in the Indian literature.
M Seyhan33 et al in their study found that among the 37 children
with Wilson’s disease, 11 (29.7%) were girls and 26 (70.3%) were boys.
In  concordance  with  the  above  studies,  our  study  too  showed  a
male predominance with 66.7% males and 33.3% females.
DURATION
In our study, the mean duration of the disease was 21.7 months
.The  range  being  1  week  to  9  years.  Majority  of  the  patients  had  the
disease for more than 6 months with 2 children having the disease for
more than 5 years.
Panagariya67 A  et  al  showed  in  their  study  the  mean  to  be  25.2
months.
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FAMILY HISTORY
Of the 30 patients in our study, 7 patients (23.3 %) had family
history of similar illness with 3 patients who had death of a sibling due
to the disease. Stephania66 et al in their study too found that 6 patients
(35%) who had positive family history were identified by family
screening. Thus family screening should be emphasized.
TREATMENT
Among the 30 patients, 19 patients (63.3%) had undergone
treatment and 11 patients (36.6%) were treatment naïve. The mean
duration of the treatment was 32.4 months, the range being 2 months to
9 years.
Among the treated patients, 78.9% were on tablet D-penicillamine
and 21% were on tablet Zinc.
M Seyhan33 et al in their study of Wilson’s disease found that 13
(35.1%) were newly diagnosed patients, whereas the other 24 had been
on d-penicillamine and zinc therapy for 3 months – 7 years (mean, 2.4 ±
2.6 years).
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Various skin manifestations due to penicillamine therapy have
been reported in Wilson’s disease, none of our patients had such
manifestations.
SYSTEMIC ONSET
In our study 73.3% patients had hepatic onset of the disease and
26.7% patients had neurological onset of the disease.
M Seyhan33 et  al  in  their  study  found  that  out  of  37  Wilson’s
disease patients, 22 (59.6%) had hepatic presentation.
Stephania66 et al in their study observed that the hepatic form was
the most prevalent (65%), as observed in our study. Raiamani68 et al in
their study found that 11 patients had hepatic form.
 Yuce34 et al observed six cases of fulminant hepatitis in a sample
of 33 children with Wilson’s disease.
KAYSER-FLEISCHER RING
Among the 30 patients, 53.3% of them presented with KF ring;
out of which 68.7% had hepatic onset of disease and 31.2% had
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neurological onset of disease. Of the patients with KF ring, 56.2% were
on treatment and 43.7% were treatment naïve.
Stephania66 et al observed that KF rings were detected in seven
cases (41%), all with severe or chronic liver disease and with ages
varying from seven to 12 years (mean: 10.6 years).
Bem RS69 et al found Kayser-Fleischer rings in 55.6% of patients.
The reported frequency of KF ring in various Indian series have been
nearly the same and ranged from 86.6 to 97.1%.
Gow PJ70 et al in their study showed that KF rings are present in
only 50% to 62% of patients with mainly hepatic disease at the time of
diagnosis as concordant with our study.
Thus KF ring was found more in the hepatic onset of disease and
was not related to the treatment.
MALNUTRITION
Malnutrition as measured by low weight for age percentiles was
found in 5 patients (16.7%), out of which 4 had hepatic onset and 1
neurological onset.
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M Seyhan33 et al in their study observed that malnutrition was
detected in four children (10.8%). Of children with malnutrition, 75%
had dermatological findings as seen in our study.
DERMATOLOGICAL MANIFESTATIONS
93.3% had atleast one cutaneous, mucosal, hair or nail findings.
27 patients (96.4 %) had cutaneous findings, 11 patients (39.2%) had
mucosal findings, 14 patients (50%) had hair findings and 18 patients
(64.2%) had nail findings. 4 patients had all the above findings.
According to M Seyhan33 et  al,  26  (70.3%)  had  at  least  one
dermatological finding. 25 (67.6%), 5 (13.5%), 9 (24.3%) had at least
one skin, mucosal and nail findings, respectively.
CUTANEOUS MANIFESTATION
Of the cutaneous manifestations, xerosis was the most common
manifestation in 70.3 % patients, followed by pigmentation in 40.7 %
and infection in 33.3 %. Icterus and pruritus were seen in 6 patients
(22.2 %) each and were associated with portal hypertension in 5 patients
(83.3 %).
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According to M Seyhan33 et al, the most prevalent cutaneous
manifestation was xerosis with a frequency of 45.7% (n -17) and
pruritus was observed in 9 patients (24.3 %) with portal hypertension as
concordant with our study.
PIGMENTARY CHANGES
Pigmentary changes in the form hyperpigmentation was observed
in 8 patients (29.6%) mainly involving the lower extremities, out of
which 7 patients had hepatic onset, 5 patients associated with portal
hypertension .Pityriasis alba was observed in 2 patients (7.4 %), both
were malnourished. Acanthosis nigricans was observed in one patient.
According to M Seyhan33 et al, hyperpigmentation was observed
in 3 patients (8.1 %) and pityriasis alba in 2 patients (5.4 %).
VASCULAR CHANGES
The vascular changes were seen in 16.6 % patients mainly
associated with portal hypertension.
According to M Seyhan33 et al, 10.8 % patients had vascular
changes.
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XEROSIS
Xerosis was the most common manifestation in our study in 70.3
% patients and occurred in all children with malnutrition. It was seen in
52.6 % treated patients and 47.3 % treatment naïve patients.
Of the 19 patients with xerosis, 78.9 % of patients had hepatic
onset and the remaining had neurological onset.
M Seyhan33 et al observed xerosis mainly on the lower limbs to
be the most common cutaneous manifestation in 17 patients.
In a study from Turkey, the frequency of xerosis was reported as
11.8% in healthy children. Thus it seems that the prevalence of xerosis
in children with WD is higher than in the healthy pediatric population.
Xerosis was thus more common in hepatic onset of the disease
and was related to the chronic course of the disease.
Although the exact pathophysiological mechanism of xerosis in
Wilson’s  disease  is  not  clear,  it  may  probably  be  due  to  the  chronic
course of the disease or due to low copper diet61.
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INFECTIONS
In our study, 30 % of patients had infections. The common
infections encountered were pityriasis versicolor, wart, molluscum
contagiosum, impetigo and scabies.
According to M Seyhan33 et al, herpes simplex, pityriasis
versicolor, warts were seen in 1 patient each.
MUCOSAL INVOLVEMENT
In our study, mucosal involvement was seen in 36.7% of patients.
6 patients had cheilitis out of which 2 children were malnourished. Oral
candidiasis and hyperpigmentation of the tongue were also seen.
M Seyhan33 et al also found in his study, the most common
mucosal finding is cheilitis (10.8%).
HAIR INVOLVEMENT
In our study, hair involvement was seen in 46.6%. Trichomegaly
was the most common manifestation seen in 9 patients (64.3%) followed
by sparse hair.
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TRICHOMEGALY
Trichomegaly was one of the common hair manifestation found in
our study. Out of the 9 patients with trichomegaly; 7 patients were on
treatment (D-penicillamine in 5) and 8 of the patients had associated KF
ring.
M Sehgal33 et al in their study observed trichomegaly in1
patient(2.7 %).
Trichomegaly is the excessive growth of the eyelashes and is a
relatively rare cosmetic disorder that can occur as a part of congenital
syndromes. The other acquired causes include HIV, autoimmune disease
and drugs like phenytoin, zidovudine, latanoprost, cyclosporine and D-
penicillamine71.
The association of trichomegaly with D-penicillamine needs
further studies as observed in our study.
NAIL INVOLVEMENT
According to our study, nail involvement was seen in 60%
patients. The common nail finding was leuconychia seen in 9(30 %)
patients, followed by clubbing, pitting and Beau’s lines.
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M Seyhan33 et al also observed that the most common nail finding
was leuconychia (18.9%)
Blue lunula, a specific finding of the disease was not detected in
both the studies.
INVESTIGATIONS
The investigations done were routine investigations to confirm the
diagnosis including routine liver function tests, Serum ceruloplasmin
levels and 24 hr urinary copper levels. MRI of brain in cases of neuro
Wilson and USG abdomen, upper GI scopy in cases of hepatic onset
disease were done.
Stephania66 et al observed that 14 patients underwent abdominal
ultrasonography and 64% had complications such as
hepatosplenomegaly and signs of cirrhosis.
SKIN BIOPSY
In our study, skin biopsy was done from the normal skin in 10
patients  and  it  showed that  the  skin  was  normal  on  H&E stain  and  on
Rhodanine staining and there were no deposits of reddish brown copper
in the dermis or periappendageal areas.
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In Wilson’s disease, there is excessive deposition of copper in
brain, liver, eyes and the excessive copper spillover is also seen in the
dermis of skin. Very few studies have been done regarding the copper
deposition in the skin and our study has shown that the copper deposits
are not seen in the skin. Furthermore biopsy was done from the normal
skin  of  the  patients  and  all  10  of  them  were  on  treatment  and  hence
further studies are required to confirm or dispute the finding.
SERUM CERULOPLASMIN
Eve AR72 et  al  have  shown  that  5-15%  of  individuals  with  WD
may have normal or only slightly reduced ceruloplasmin, whereas 10-
20% of heterozygotes may have reduced serum ceruloplasmin. A serum
ceruloplasmin level less than 20 mg/dL has been considered consistent
with WD and diagnostic if associated with KF rings as observed in our
patients.
24 HOURS URINARY COPPER
24 hour urinary copper was found to be normal in 14 patients in
our study and 8 patients had values between 300 to 600 microgram/ 24
hours.
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Sanchez-Albisua L63 et al have found that basal 24-hour urinary
copper excretion may be less than 100 ?g at presentation in 16% to 23%
of patients diagnosed with WD.
MRI FINDINGS
MRI findings of increased T2 intensities in Basal ganglia (Globus
pallidus)  were  seen  in  6  patients  (75  %)  of  Wilson  disease  with
neurological onset in our study.
Panagariya67 A et al have observed in their study on neuro
Wilson’s disease, abnormal findings in basal ganglia in 86% patients.
Bem69 R S et al have found in their study neuroradiological
imaging abnormalities in 72.2% of these patients.
ENDOSCOPY
Upper gastrointestinal endoscopy was done for 6 patients with
portal hypertension features and hepatic onset of the disease.
Stephania66 et al in their study observed 7 patients who underwent
upper GI endoscopy as they showed signs of portal hypertension and
43% had esophageal varices.
SUMMARY
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SUMMARY
1. In our study of Wilson’s disease most of the patients were in the
age group of 6 to 9 years (40 %), followed by the 13 to 16 years
(33.3%).
2. The mean age in the study was 10.7 ± 2.9 years and the range 6 –
16 years.
3. Among the 30 patients, 20(66.7%) were male and 10(33.3%)
were females. The male to female ratio was found to be 2:1.
4. The mean duration of the disease was 21.7 months .The range
being 1 week to 9 years.
5. Of the 30 patients, 7 patients (23.3 %) had family history of
similar illness with 3 patients who had death of a sibling due to
the disease.
6. Among the 30 patients, 19 patients (63.3%) had undergone
treatment and 11 patients (36.6%) were treatment naïve.
7. The mean duration of the treatment was 32.4 months, the range
being 2 months to 9 years.
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8. Among the treated patients, 78.9% were on tablet D-penicillamine
and 21% were on tablet Zinc.
9. In our study, 73.3% patients had hepatic onset of the disease and
26.7% patients had neurological onset of the disease.
10.Among the 30 patients, 53.3% of them presented with KF ring;
out of which 68.7% had hepatic onset of disease and 31.2% had
neurological onset of disease.
11.Malnutrition as measured by low weight for age percentiles was
found in 5 patients (16.7%)
12.Out of the 30 patients, 93.3% had atleast one cutaneous, mucosal,
hair or nail findings. 96.4 % had cutaneous findings, 39.2% had
mucosal findings, 50 % had hair findings and 64.2% had nail
findings.
13.Xerosis was the most common cutaneous manifestation in 70.3%
patients, followed by pigmentation in 40.7 % and infection in
30%.
14.Icterus and pruritus were seen in 6 patients (22.2 %) each and
were associated with portal hypertension in 5 patients (83.3 %).
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15.Pigmentary changes in the form hyperpigmentation were
observed in 8 patients (29.6%) mainly involving the lower
extremities.
16. The vascular changes like spider nevi, purpura were seen in 16.6
% patients associated with portal hypertension.
17.Xerosis, the most common manifestation occurred in all children
with malnutrition. It was seen in 52.6 % treated patients and 47.3
% treatment naïve patients.
18.In our study, 30 % of patients had infections. The common
infections encountered were pityriasis versicolor, wart,
molluscum contagiosum, impetigo and scabies.
19.Mucosal involvement was seen in 36.7% of patients, the most
common manifestation being cheilitis.
20. Trichomegaly was one of the common hair manifestation found
in our study in 9 patients(64.3%) out of which 7 were on
treatment.
21. Nail involvement was seen in 60% patients. The common nail
finding was leuconychia seen in 9(30 %) patients.
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22.Skin biopsy from 10 patients showed that the skin was normal on
H&E stain and on Rhodanine staining and there were no deposits
of reddish brown copper in the dermis or periappendageal areas.
23.In our study, 6 patients had serum ceruloplasmin levels less than
20 mg/dl and 24 patients had levels between 20 – 50 mg/dl.
24.The 24 hour urinary copper levels was found to be normal in 14
patients in our study and 8 patients had values between 300 to 600
microgram/ 24 hours.
25.MRI findings of increased T2 intensities in Basal ganglia (Globus
pallidus)  were  seen  in  6  patients(75  %)  of  Wilson  disease  with
neurological onset in our study.
26.Upper gastrointestinal endoscopy was done for 6 patients with
portal hypertension features.
27.In our study,  there was 1 patient  who died due to hepatic failure
with severe portal hypertension.
CONCLUSION
100
CONCLUSION
1. Wilson’s disease is more common in males with a male to female
ratio of 2:1.
2. Skin changes in Wilson’s disease are minor and very few patients
come to dermatologist early.
3. Xerosis was the most common cutaneous manifestation in our
study as with previous studies.
4. Trichomegaly was one of the common association we found in
the study and in patients on long term D-penicllamine therapy but
further studies are required to confirm it.
5. Blue lunulae of nails though said to be a specific manifestation
was not found in our patients.
6. D-Penicillamine although associated with specific cutaneous side
effects, was not found in our study.
7. The skin biopsy from the patients did not show any deposits of
copper seen by copper staining.
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8. Dermatologists should be aware of the various dermatological
manifestations of Wilson’s disease and cutaneous side effects of
D-Penicillamine.
9. Although cutaneous manifestations are non - specific in Wilson’s
disese, it is mandatory to have an astute dermatological
examination of all patients with the disease.
10.Wilson’s disease is probably more common than reported from
India. There is the need for further epidemiological studies and
also multicentric studies in view of the high degree of
consanguinity in many parts of India, particularly south India.
11.A nationwide registry for the disease may also improve awareness
among the medical communities.
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ANNEXURES
ABBREVIATIONS
WD : Wilson’s disease
KF ring : Kayser Fleischer ring
BAL : British Anti- lewisite
PRNP : Prion protein
CBP : Copper binding proteins
IAP : Inhibitors of apoptosis proteins
24 hr Cu : 24 hours Urinary Copper excretion
MASTER CHART


MASTER CHART CODING
PENCI –  PENICILLAMINE
D OF Rx – DURATION OF TREATMENT
HEP – HEPATIC
PORT HT – PORTAL HYPERTENSION
NEURO – NEUROLOGICAL
KF RING –  KAYSER- FLEISCHER RING
MALNU –  MALNUTRITION
VAS – VASCULAR
TRICHOM – TRICHOMEGALY
LEUCO – LEUCONYCHIA
CERU – CERULOPLASMIN
M – MALE
F – FEMALE
HYP – HYPERPIGMENTATION
PA – PITYRIASIS ALBA
AN – ACANTHOSIS NIGRICANS
SPI – SPIDER NEVI
PUR – PURPURA
PER – PALMAR ERYTHEMA
PV – PITYRIASIS VERSICOLOR
IMP – IMPETIGO
WA – WART
SCA – SCABIES
MC – MOLLUSCUM CONTAGIOSUM
CAM –  CAFÉ AU LAIT MACULES
AC  – ACNE
SD – SEBORRHEIC DERMATITIS
KP – KERATOSIS PILARIS
GYN – GYNAECOTHELIA
AD – ATOPIC DERMATITIS
ATR – ATROPHY
URT – URTICARIA
PHR – PHRYNODERMA
STR – STRIAE
PIG – PIGMENTATION
BEA – BEAU ‘S NAILS
MRI – MAGNETIC RESONANCE IMAGING
OGD – UPPER ESOPHAGEAL SCOPY
PROFORMA
Patient’s name: Parent / Guardian’s name:
Age:
Sex:
Skin OP no: GE No:
Address:
Phone no:
Duration of disease:
Naïve patient:
Treated patient:
Duration < 5 years Duration > 5 years
HISTORY :
Pregnancy and birth H/o:
Developmental H/o:
Nutritional H/o:
Immunization H/o:
Family H/o:
Treatment H/o:
GENERAL EXAMINATION:
ANTHROPOMETRY:
Height:
Weight:
SYSTEMIC EXAMINATION:
CVS:
RS:
Abdomen:
CNS:
Ophthalmological examination:
CUTANEOUS EXAMINATION:
SKIN:
MUCOSA:
HAIR:
NAIL:
INVESTIGATIONS
1. Blood haemogram:
2. LFT:
3. Serum ceruloplasmin levels:
4. 24 hour urinary copper levels:
5. Imaging studies:
6. Upper gastrointestinal scopy:
7. Histopathological examination :
- Special stain for copper
INFORMATION TO PARTICIPANTS
Name of Investigator: Dr.Karrunya.K.J
Name of Participant:
You are invited to take part in this study. The information in this
document is meant to help you decide whether or not to take part. Please
feel free to ask if you have any queries or concerns.We are conducting a
study on:“SPECTRUM OF CUTANEOUS MANIFESTATIONS IN
WILSON’S DISEASE-NAÏVE PATIENTS AND PATIENTS ON
TREATMENT” among patients attending Rajiv Gandhi Government
General Hospital, Chennai and for that your participation may be
valuable to us.
? The purpose of this study is to determine the various cutaneous
manifestations in diagnosed Wilson’s disease children, both in
naïve patients and patients on treatment.
? The study involves basic investigations and the visualisation of
the skin, hair, mucosa and nails and appropriate biopsy of lesions
when necessary.
? You may have to bring your child to the hospital for examination
and investigations apart from your scheduled visits, if required.
? The privacy of the patients in the research will be maintained
throughout the study. In the event of any publication or
presentation resulting from the research, no personally
identifiable information will be shared.
? Taking part in this study is voluntary.You are free to decide
whether your child will participate in this study or withdraw at
any time; your decision will not result in any loss of benefits to
which your child is otherwise entitled.
? The results of the special study may be intimated to you at the end
of the study period or during the study if anything is found
abnormal which may aid in the management or treatment.
Signature of Investigator Signature of the Participant
Date :
PATIENT CONSENT FORM
Title of the study: “SPECTRUM OF CUTANEOUS
MANIFESTATIONS IN WILSON’S
DISEASE-NAÏVE PATIENTS AND
PATIENTS ON TREATMENT”
Name of the Participant:
Name of the investigator: Dr.Karrunya.K.J
Name of the Institution: Rajiv GandhiGovernment
General Hospital, Chennai
Documentation of the informed consent
I ___________________________ have read the information in
this form (or it has been read for me). I was free to ask any questions
and they have been answered. The assent of my child has been asked. I
am over 18 years of age and exercising my free power of choice, hereby
give my consent to include my child as a participant in the study.
1. I have read and understood this consent form and the information
provided to me. I understand, about the purpose, nature of study and
various investigations to becarried out for the study.
2. I have had the consent document explained to me.
3. I  have  been  informed  about  the  duration  of  study  &  possible
complication caused by study.
4. My rights and responsibilities have been explained to me by the
investigator.
5. I have informed the investigator of all the treatments the child is
taking or has taken in the past 1 year including any native
(alternative) treatment.
6. I give full consent for my child being enrolled in the above study,
including special tests and skin biopsies.
7. My child has not participated in any research study at any time .
8. I  am  aware  of  the  fact  that  I  can  opt  out  of  the  study  at  any  time
without having to give any reason and this will not affect my future
treatment in this hospital.
9. I hereby give permission to the investigators to release the
information obtained from me as a result of participation in this study
to the sponsors, regulatory authorities, Govt agencies and IEC.I
understand that they are publicly presented.
10.My child’s  identity will  be kept  confidential  if  the data are publicly
presented.
11.I have had my questions answered to my satisfaction.
12.I have decided to make my child take part in the research study.
13.I  am  aware  that  if  I  have  any  question  during  this  study,  I  should
contact at one of the addresses listed above. By signing this consent
form I attest that the information given in this document has been
clearly explained to me and apparently understood by me. I will be
given a copy of this consent document.
Participant’s initials:_______________
Whether child’s assent was asked: Yes / No (Tick one)
[If the answer to be above question is yes, write the following phrase:
You agree with the manner in which assent was asked for from your
child and given by yourchild. You agree to have your child take part in
this study].
[If  answer  to  be  above  question  No,  give  reason  (s)
:___________________________________.
Although your child did not or could not give his or her assent, you
agree to your child’sparticipation in this study.
Name and Signature of / thumb impression of the participant’s parent(s)
(or legal representative)
Name_________________________ Signature_________________
Date________________
Name and Signature of the investigator or his representative obtaining
consent :
Name_________________________ Signature_________________
Date________________


